Welcome to our dedicated page for AN2 Therapeutics SEC filings (Ticker: ANTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AN2 Therapeutics, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage biopharmaceutical company developing small-molecule therapeutics from a boron chemistry platform. Its disclosures cover common stock registration, operating and financial results, clinical and regulatory updates, risk factors and material events related to its development pipeline.
ANTX filings also include proxy materials for director elections and auditor ratification, 8-K reports on material agreements, equity and warrant financing arrangements, at-the-market sale agreements, equity incentive plan matters, option repricing, officer appointments, governance changes and capital-structure disclosures.
AN2 Therapeutics, Inc. (ANTX) director Robin Shane Readnour reported indirect sales totaling 1,108 shares of common stock on September 9, 2026, at a weighted average price of $6.0243 per share. The sales were made automatically under Rule 10b5-1 trading plans for MGC 2018 LP and MGC 2018 QP. Following these transactions, Readnour continues to hold 9,077 shares of ANTX common stock directly, while disclaiming beneficial ownership of the fund-held shares beyond any pecuniary interest.
AN2 Therapeutics, Inc. (ANTX) director Robin Shane Readnour reported indirect sales of common stock associated with investment funds MGC Venture Partners 2018, LP and MGC Venture Partners QP 2018, LP on September 3 and 8, 2026. The funds sold a total of 16,119 shares at weighted average prices of $6.0183 and $6.0698 per share, for transactions occurring automatically pursuant to Rule 10b5-1 trading plans adopted on April 23, 2026. Readnour has shared voting and dispositive power over these fund-held shares and disclaims beneficial ownership except to the extent of his pecuniary interest; a separate entry shows 9,077 shares of common stock held directly as of September 3, 2026.
AN2 Therapeutics, Inc. (ANTX) reported that Principal Accounting Officer Sarah Joanne Williams sold 272 shares of common stock on September 1, 2026 at $5.53 per share. The sale was made pursuant to the grant terms to satisfy tax withholding obligations arising from RSU vesting on August 28, 2026.
After this transaction, Williams holds 66,311 shares directly, including RSUs that vest through 2029, subject to her continuous service. No Rule 10b5-1 trading plan is reported for this sale.
AN2 Therapeutics, Inc. (ANTX) director Margaret M. FitzPatrick purchased 2,098 shares of ANTX common stock in a direct open-market or private transaction on September 1, 2026 at $5.53 per share. Following this purchase, she directly holds 10,708 shares of ANTX common stock. No Rule 10b5-1 trading plan is reported.
AN2 Therapeutics, Inc. (ANTX) reported that Trenor Cameron C. III, its Chief Medical Officer, filed an initial statement of beneficial ownership on Form 3. The filing lists no reportable transactions or holdings data, serving as the baseline ownership record as this officer becomes a reporting person.
AN2 Therapeutics, Inc. (ANTX) director Robin Shane Readnour reported indirect sales of common stock on August 17, 2026 through investment partnerships MGC Venture Partners 2018, LP and MGC Venture Partners QP 2018, LP under pre-arranged Rule 10b5-1 trading plans. A total of 35,402 shares of ANTX common stock were sold in open-market or private transactions at a weighted average price of $6.0082 per share, with individual trades ranging from $6.00 to $6.07. Readnour is a managing partner of MGC Venture Partners 2018 GP, LLC, which has shared voting and dispositive power over the partnerships’ holdings, and disclaims beneficial ownership of these securities except to the extent of her pecuniary interest. Separately, she reports 9,077 shares of ANTX common stock held directly.
ANTX filed a notice indicating an intention to sell common stock. The filing lists 1,012,000 shares of common stock associated with a value of $6,080,268.00, alongside another share figure of 37,736,237, in connection with the issuer’s Nasdaq-listed stock. The proposed sales relate to shares previously acquired from the issuer on several dates between 2019 and 2022.
AN2 Therapeutics director Joseph S. Zakrzewski reported a bona fide gift of 405,880 shares of common stock. The gifted shares were held indirectly through the Z3 Trust, and he disavows beneficial ownership of those shares. Following this transaction, he reports 145,538 shares of AN2 Therapeutics common stock held directly.
AN2 Therapeutics, Inc. reported its June 30, 2026 quarter as a clinical‑stage company with no product revenue and continued R&D investment across hematologic, infectious disease and oncology programs. The pipeline includes three Phase 2 studies expected to be active in 2026 and multiple preclinical candidates.
For the quarter, net loss was $8.2 million versus $6.5 million a year earlier, driven mainly by higher research and development expenses of $6.0 million. General and administrative expenses declined to $2.9 million. Six‑month net loss was $18.2 million compared with $17.1 million in the prior‑year period.
Liquidity improved through financings. As of June 30, 2026, cash, cash equivalents and investments totaled $79.9 million, up from $61.9 million at year‑end, reflecting a March 2026 private placement of common stock and pre‑funded warrants and sales under a new at‑the‑market equity program. Management states these resources are expected to fund the current operating plan for at least twelve months from the financial statement issuance date.
AN2 Therapeutics, Inc. reported second quarter 2026 results and highlighted pipeline progress built on its boron chemistry platform. Three Phase 2 programs are expected to be underway by year-end, targeting polycythemia vera, M. abscessus lung disease, and chronic Chagas disease, alongside an ENPP1 oncology candidate.
For the quarter ended June 30, 2026, research and development expenses were $6.0 million and general and administrative expenses were $2.9 million, leading to a net loss of $8.2 million, or $0.18 per share, compared to $6.5 million, or $0.21 per share, a year earlier. Cash, cash equivalents and investments totaled $79.9 million, and the company projects this will fund operations into 2029 under its current plan.
Operationally, AN2 is expanding a global Phase 2 study of oral epetraborole in polycythemia vera following a pre-IND meeting with the FDA, with enrollment planned to begin in the fourth quarter of 2026 and Part 1 data expected periodically through 2027. Enrollment continues in an 84‑patient, randomized, double-blind, placebo-controlled investigator-initiated Phase 2 trial in M. abscessus lung disease, with topline data anticipated in late 2027.